최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0066487 (2006-09-11) |
등록번호 | US-9427419 (2016-08-30) |
국제출원번호 | PCT/US2006/035320 (2006-09-11) |
§371/§102 date | 20090122 (20090122) |
국제공개번호 | WO2007/033082 (2007-03-22) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 334 |
The invention relates generally to compositions comprising dimethylsulfoxide (DMSO) and associated compounds in combination with one or more of the following: fructose 1,6-diphosphate, L-arginine, L-lysine, L-aspartate, and urea. Methods for treating traumatic brain injury, ischemic stroke, atherosc
The invention relates generally to compositions comprising dimethylsulfoxide (DMSO) and associated compounds in combination with one or more of the following: fructose 1,6-diphosphate, L-arginine, L-lysine, L-aspartate, and urea. Methods for treating traumatic brain injury, ischemic stroke, atherosclerosis, spinal cord trauma, and neurodegenerative illnesses are also provided.
1. A method of treating brain injury, the method consisting essentially of: administering a composition consisting essentially of dimethylsulfoxide (DMSO), L-arginine and one or more pharmaceutically-acceptable carriers to a brain injury patient,wherein the DMSO is present in a concentration range o
1. A method of treating brain injury, the method consisting essentially of: administering a composition consisting essentially of dimethylsulfoxide (DMSO), L-arginine and one or more pharmaceutically-acceptable carriers to a brain injury patient,wherein the DMSO is present in a concentration range of about 20% to about 40% in the composition,wherein the L-arginine is present in a range of about 0.5% to about 10% weight per volume of the composition,wherein the administering is intravenous, andwherein the brain injury is a spinal cord injury or a traumatic brain injury. 2. The method of claim 1, further comprising preparing the composition prior to the administering, wherein the preparing comprises combining at least the DMSO and the L-arginine. 3. The method of claim 1, wherein the DMSO is present in the composition in has a concentration in a range of about 20% to about 30%. 4. The method of claim 1, wherein the DMSO is present in in the composition in a concentration of about 28%. 5. The method of claim 1, wherein the pharmaceutically-acceptable carrier is saline. 6. A method of treating a patient with brain injury, said method comprising: obtaining a composition comprising dimethylsulfide (DMS) and L-arginine in a therapeutically effective dose,wherein said therapeutically effectively dose of DMS is a concentration of about 20% to 40% of said composition and said therapeutically effective dose of L-arginine is about 0.5% to about 10% weight per volume of said composition; andadministering said composition intravenously to said patient, wherein said brain injury is a spinal cord injury or a traumatic brain injury. 7. The method of claim 6, further comprising administering at least one of methylsulfonylmethane (MSM), urea, and dimethylsuloxide (DMSO). 8. The method of claim 7, wherein the administering at least one of methylsulfonylmethane (MSM), urea, and dimethylsulfoxide (DMSO) comprises administering orally. 9. The method of claim 6, wherein the dimethylsulfide (DMS) is present in said composition in a concentration of about 28%. 10. The method of claim 6, wherein said composition further comprises a compound selected from the group consisting of one or more of the following: L-lysine and L-aspartine. 11. The method of claim 6, wherein said composition further comprises urea in a concentration in a range of about 20% to about 60%. 12. The method of claim 11, wherein at least one of said DMSO, said L-arginine, and said urea is administered intravenously at a rate of about 10 ml/min. 13. A method of increasing blood flow in the central nervous system, consisting essentially of: intravenously administering a therapeutically effective dose of a pharmaceutical composition consisting essentially of dimethylsulfoxide (DMSO), L-arginine, and one or more pharmaceutically-acceptable carriers to a subject having a spinal cord injury or a traumatic brain injury. 14. A method of treating brain injury, consisting essentially of: administering a therapeutically effective dose of a pharmaceutical composition consisting essentially of dimethylsulfoxide (DMSO), L-arginine, urea, and one or more pharmaceutically-acceptable carriersto an individual having a brain injury, wherein said brain injury comprises a spinal cord injury or a traumatic brain injury. 15. A method of treating brain injury, the method consisting essentially of: administering a composition consisting essentially of DMSO, L-arginine and one or more pharmaceutically-acceptable carriers to a brain injury patient,wherein said DMSO is present in a concentration range of about 20% to about 40% in the first composition,wherein said L-arginine is present in a range of about 0.5% to about 10% weight per volume of said first composition,wherein said brain injury is a spinal cord injury or a traumatic brain injury. 16. A method of treating brain injury, consisting essentially of: administering a therapeutically effective dose of a pharmaceutical composition consisting essentially of dimethylsulfoxide (DMSO), L-arginine, MSM, and one or more pharmaceutically-acceptable carriersto an individual having a brain injury, wherein said brain injury comprises a spinal cord injury or a traumatic brain injury. 17. A method of treating brain injury, comprising: administering a therapeutically effective dose of a composition comprising dimethylsulfide (DMS), L-arginine, MSM, and one or more pharmaceutically-acceptable carriers to an individual having a brain injury, wherein said brain in jury comprises a spinal cord injury or a traumatic brain injury. 18. A method of treating brain injury, comprising: administering a therapeutically effective dose of a pharmaceutical composition comprising dimethylsulfide (DMS), L-arginine, urea, and one or more pharmaceutically-acceptable carriers to an individual having a brain injury, wherein said brain injury comprises a spinal cord injury or a traumatic brain injury. 19. A method, comprising: administering a composition to a patient, the composition consisting essentially of:dimethylsulfoxide (DMSO),at least one of L-arginine, L-lysine, L-aspartate, dimethylsulfide (DMS), methylsulfonylmethane (MSM), and urea, andone or more pharmaceutically-acceptable carriers. 20. The method of claim 19, wherein the patient is a brain injury patient. 21. The method of claim 20, wherein the brain injury is a spinal cord injury or a traumatic brain injury. 22. A method, comprising: administering a composition to a patient, the composition comprising: dimethylsulfide (DMS),at least one of L-arginine, L-lysine, L-aspartate, dimethylsulfoxide (DMSO), methylsulfonylmethane (MSM), and urea, andone or more pharmaceutically-acceptable carriers. 23. The method of claim 22, wherein the patient is a brain injury patient. 24. The method of claim 23, wherein the brain injury is a spinal cord injury or a traumatic brain injury.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.